News & Analysis as of

Capital Markets › Startups › Life Sciences

Cooley LLP

Deal Count Increases and Invested Capital Down for Late-Stage Rounds; Valuations Rise and Pay-to-Play Reaches 10.1%

Cooley LLP on

Cooley handled 238 reported venture capital financings in Q2 2025, representing $6.5 billion of invested capital. Deal count increased by more than 20% across all stages of financing compared to the previous quarter, with...more

Orrick, Herrington & Sutcliffe LLP

From Federal to State: Building the New Life Sciences Capital Stack | Life Sciences Snapshot – Q3 2025

Orrick, Herrington & Sutcliffe LLP on

This year, U.S. VC funding into the life sciences sector has cooled: Q1 softness was followed by a decade low in VC transactions in Q2. Despite the moderation in dealmaking volume, investors continued to deploy sizable...more

Wilson Sonsini Goodrich & Rosati

[Event] Biotech Summit 2024 - October 9th - 10th, Boston, MA

Wilson Sonsini Goodrich & Rosati on

Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more

Orrick, Herrington & Sutcliffe LLP

Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2023

Orrick, Herrington & Sutcliffe LLP on

This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2023 include: • Life sciences VC deal value totaled $5.0 billion across 364 deals, representing a 40.9% decline in value...more

Morgan Lewis

Key IP Considerations for CVC Investments in the Life Sciences Industry

Morgan Lewis on

Japanese corporate venture capital (CVC) investments in the life sciences industry provide investors entry into a market by supporting the development of innovative products and services. But these innovations, and thus the...more

Fenwick & West LLP

Life Sciences Summit: Biotech IPO Market Shows Signs of Life

Fenwick & West LLP on

As biotech markets begin to show signs of life, how should company leaders and investors prepare for what’s next?  Biotech executives, investment bankers and partners from Deloitte’s life sciences practice and Fenwick’s...more

Fenwick & West LLP

Silicon Valley Venture Capital Survey - Fourth Quarter 2021

Fenwick & West LLP on

Our survey analyzed the terms of 287 venture financings closed in the fourth quarter of 2021 by companies headquartered in Silicon Valley. Key Findings - • Valuation results again reached new record highs, with the...more

Fenwick & West Life Sciences Group

Economic Conditions Changing, but Digital Health Still Strong

Fenwick & West Life Sciences Group on

The digital health sector emerged as a juggernaut during the COVID-19 pandemic, with almost $15 billion invested in privately-held digital health companies in 2020 and nearly $30 billion invested last year, according to our...more

Troutman Pepper Locke

To IPO, Or Not to IPO, That Is the Question - How to prepare for and execute a successful public offering

Troutman Pepper Locke on

More than ever, life sciences companies are going public to raise capital for future growth. In fact, U.S. equity financing in life sciences skyrocketed to a record $7 billion in 2018—a 69 percent jump over the year before. ...more

9 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide